RiPro: alterations of ribosomal proteins in cancer and in rare diseases
We study the impact of alterations in genes encoding ribosomal proteins, with the aim of understanding their role in disease pathogenesis and assessing their potential as novel therapeutic targets.
Research areas
Our group investigates the role of alterations in genes encoding ribosomal proteins in the development of various human diseases.
We focus on both inherited disorders, such as Diamond-Blackfan Anemia (DBA), and acquired diseases, including:
- High-grade serous ovarian carcinoma
- T-cell acute lymphoblastic leukemia (T-ALL)
- Osteosarcoma
We actively collaborate with research groups across Italy and Europe to study ribosomal and protein synthesis machinery alterations in both inherited and acquired pathological contexts.
Ongoing Research Projects
- Role of ribosomal alterations in T-cell acute lymphoblastic leukemia
- Role of RPL8 gene amplification in high-grade serous ovarian carcinoma
- Molecular pathogenesis and novel therapies for Diamond-Blackfan Anemia
Research Objectives
Our research activity is structured on two integrated levels:
- Basic Research
We investigate the molecular and cellular impact of alterations in ribosomal protein genes to understand the mechanisms underlying the diseases we study. - Translational Research
We translate our findings into clinical applications by identifying diagnostic and prognostic biomarkers and novel therapeutic targets, aiming to develop personalized medicine approaches.
responsible
-
Associate Professor
Dipartimento di Scienze Mediche e Chirurgiche - DIMEC
Via Massarenti 9
Bologna (BO)
Tel: +39 051 20 9 4766
LABORATORI DI RICERCA